Amarin Corp Plc (AMRN)

[AtlasSnuggled]

William R. Hiatt,, M.D. Endocrinologic/Metabolic Advisory Committee Member

some dd

CURRICULUM VITAE (2012)
William R. Hiatt, MD, FACP, FAHA
Novartis Foundation Professor for Cardiovascular Research Section of Vascular Medicine Division of Cardiology University of Colorado School of Medicine President, CPC Clinical Research

http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM354664.pdf

108. Sommerfield T, Hiatt WR. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev 2004;3:CD003833.

Omega-3 fatty acids for intermittent claudication.
http://www.ncbi.nlm.nih.gov/pubmed/17943801

Abstract
BACKGROUND:
Omega-3 fatty acids are established as being effective in the treatment and prevention of coronary artery disease. It is possible that they may also benefit people with peripheral arterial disease, since the pathogenesis of the two conditions is similar.

MAIN RESULTS:
Six studies were included representing 313 participants. All studies compared omega-3 fatty acid supplementation with placebo lasting from 4 weeks to 2 years. Two studies with long treatment periods administered additional substances, making any observed effects impossible to attribute to omega-3 fatty acids and were therefore excluded from the statistical analyses. No significant differences between intervention and control groups were observed in ankle brachial pressure index (ABPI) (weighted mean difference (WMD) -0.02; 95% CI -0.09 to 0.05), systolic blood pressure (WMD 5.00 mmHg; 95% CI -11.59 to 21.59), plasma viscosity (WMD 0.03 mPa/s; 95% CI -0.02 to 0.08), pain-free walking distance (PFWD) (WMD 7.46 m; 95% CI -25.47 to 40.39), or maximal walking distance (MWD) (WMD 0.27 m; 95% CI -39.59 to 40.13). Blood viscosity levels decreased. Gastrointestinal side effects were observed in two studies. Omega-3 fatty acid supplementation increased (low-density lipoprotein) LDL cholesterol levels (WMD 0.80 mmol/litre; 95% CI 0.34 to 1.26) and total cholesterol levels (WMD 0.64 mmol/litre; 95% CI 0.08 to 1.20).

AUTHORS' CONCLUSIONS:
Omega-3 fatty acids appear to have limited haematological benefits in people with intermittent claudication but there is no evidence of consistent improved clinical outcomes which are the primary outcomes of this review (quality of life, PFWD, MWD, ABPI, angiographic findings). Supplementation may also cause adverse effects such as increased total and LDL cholesterol levels. Further research is needed in this area, to evaluate short- and long-term effects on more clinically relevant outcomes.

~~~~~~~

https://profiles.ucdenver.edu/display/202142
Fatty Acids, Omega-6
This graph shows the total number of publications written about "Fatty Acids, Omega-6" by people in Colorado PROFILES by year, and whether "Fatty Acids, Omega-6" was a major or minor topic of these publication.

William R Hiatt
https://profiles.ucdenver.edu/display/224140

Smith RJ, Hiatt WR. Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder. JAMA Intern Med. 2013 Sep 9; 173(16):1491-2.
View in: PubMed

JAMA Intern Med. 2013 Sep 9;173(16):1491-2. doi: 10.1001/jamainternmed.2013.6624.
Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder.
Smith RJ, Hiatt WR.
Source
Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island2Ocean State Research Institute,

Berger JS, Hiatt WR. Medical therapy in peripheral artery disease. Circulation. 2012 Jul 24; 126(4):491-500.
View in: PubMed ( wont open)

http://circ.ahajournals.org/content/126/4/491.extract
Pg1 pdf